TY - JOUR
T1 - Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist
AU - Nakayama, Mieko
AU - Inoguchi, Toyoshi
AU - Sonta, Toshiyo
AU - Maeda, Yasutaka
AU - Sasaki, Shuji
AU - Sawada, Fumi
AU - Tsubouchi, Hirotaka
AU - Sonoda, Noriyuki
AU - Kobayashi, Kunihisa
AU - Sumimoto, Hideki
AU - Nawata, Hajime
N1 - Funding Information:
This work was supported by a Grant-in-Aid for Scientific Research (No. 16590888) from the Ministry of Education, Scientific and Culture, Japan.
PY - 2005/7/15
Y1 - 2005/7/15
N2 - This study was undertaken to reveal the role of NAD(P)H oxidase in increased oxidative stress in islets of Type 2 diabetes. Immunostaining analysis showed that staining intensities of NAD(P)H oxidase components, gp91phox and p22phox, significantly increased in islets of animal models of Type 2 diabetes, OLETF rats (60 weeks of age) and db/db mice (14 weeks of age), compared with age-matched controls, respectively, correlating with increased levels of oxidative stress marker, 8-hydroxy-deoxyguanosine or 4-hydroxy-2-nonenal modified protein. In db/db mice, oral administration of angiotensin II Type 1 receptor antagonist valsartan (5 mg/kg) for 4 weeks significantly attenuated the increased expression of gp91phox and p22phox together with inhibition of oxidative stress and partially restored decreased insulin contents in islets. Angiotensin II-related increased expression of NAD(P)H oxidase may play an important role in increased oxidative stress in islets of Type 2 diabetes. This mechanism may be a novel therapeutic target for preventing β-cell damage.
AB - This study was undertaken to reveal the role of NAD(P)H oxidase in increased oxidative stress in islets of Type 2 diabetes. Immunostaining analysis showed that staining intensities of NAD(P)H oxidase components, gp91phox and p22phox, significantly increased in islets of animal models of Type 2 diabetes, OLETF rats (60 weeks of age) and db/db mice (14 weeks of age), compared with age-matched controls, respectively, correlating with increased levels of oxidative stress marker, 8-hydroxy-deoxyguanosine or 4-hydroxy-2-nonenal modified protein. In db/db mice, oral administration of angiotensin II Type 1 receptor antagonist valsartan (5 mg/kg) for 4 weeks significantly attenuated the increased expression of gp91phox and p22phox together with inhibition of oxidative stress and partially restored decreased insulin contents in islets. Angiotensin II-related increased expression of NAD(P)H oxidase may play an important role in increased oxidative stress in islets of Type 2 diabetes. This mechanism may be a novel therapeutic target for preventing β-cell damage.
UR - http://www.scopus.com/inward/record.url?scp=20444407654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20444407654&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2005.05.065
DO - 10.1016/j.bbrc.2005.05.065
M3 - Article
C2 - 15922295
AN - SCOPUS:20444407654
VL - 332
SP - 927
EP - 933
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
SN - 0006-291X
IS - 4
ER -
